KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Cash & Current Investments (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Cash & Current Investments for 18 consecutive years, with $1.9 billion as the latest value for Q1 2026.

  • For Q1 2026, Cash & Current Investments fell 10.54% year-over-year to $1.9 billion; the TTM value through Mar 2026 reached $1.9 billion, down 10.54%, while the annual FY2025 figure was $2.7 billion, 16.53% up from the prior year.
  • Cash & Current Investments hit $1.9 billion in Q1 2026 for Ionis Pharmaceuticals, down from $2.7 billion in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $2.7 billion in Q4 2025 and bottomed at $1.9 billion in Q1 2026.
  • Average Cash & Current Investments over 5 years is $2.2 billion, with a median of $2.2 billion recorded in 2023.
  • Year-over-year, Cash & Current Investments grew 17.98% in 2023 and then dropped 12.86% in 2024.
  • Ionis Pharmaceuticals' Cash & Current Investments stood at $2.0 billion in 2022, then increased by 17.33% to $2.3 billion in 2023, then decreased by 1.44% to $2.3 billion in 2024, then rose by 16.53% to $2.7 billion in 2025, then dropped by 28.32% to $1.9 billion in 2026.
  • According to Business Quant data, Cash & Current Investments over the past three periods came in at $1.9 billion, $2.7 billion, and $2.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.